Modelling the temporal progression of Alzheimer's disease biomarkers
Sara Wade (University of Warwick)
Friday 5th February, 2016 15:00-16:00 Maths 522
In a clinical trial setting, designed to test the effectiveness of any proposed drugs or therapies for Alzheimer's disease (AD), accurate tools are needed for monitoring disease progression, as inclusion criteria, and for disease-staging. Studies have suggested that AD neuroimaging or biological biomarkers could be better suited to clinical trials as outcome measures to monitor disease progression than traditional clinical measures, such as the mini-mental state exam (MMSE) or the Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog), because of higher sensitivity to changes over shorter periods of time with smaller samples of patients. This could be particularly advantageous in early to mild stages of the disease, when drugs or therapies tend to be most effective. The aim of this study is to compare the temporal progression of AD biomarkers, identifying the biomarkers that display the greatest and most accurate changes early in the disease and understanding how short term changes in imaging or fluid biomarkers can predict the long term behavior of clinical outcomes.